HK Stock MarketDetailed Quotes

09926 AKESO

Watchlist

43.900
-1.500-3.30%

Market Closed Apr 19 16:08 CST

38.01BMarket Cap16.98P/E (TTM)

AKESO Stock Forum

Moomoo AI

Mar 21 07:14

Despite analysts downgrading revenue estimates and increasing loss per share forecasts for Akeso, the consensus price target remains steady. However, Akeso's revenues are expected to underperform the wider industry.

Akeso, Inc. Just Recorded A 8.5% EPS Beat: Here's What Analysts Are Forecasting Next

Moomoo AI

Mar 15 06:41

Akeso's weaker revenue outlook doesn't impact its P/S ratio as much as expected, posing a risk to investors. The share price may fall if low revenue growth affects sentiment. Investors should consider this risk before investing.

Akeso, Inc.'s (HKG:9926) 25% Price Boost Is Out Of Tune With Revenues

Spinee

Jan 17 16:21

HSI Plunge Once Deepens to 620 Pts; Pharmas In Sell-off

$Hang Seng Index(800000.HK)$ plunge deepened unceasingly after midday. It once stumbled 620 pts or 3.9% to bottom at 15,245, hitting an over-14-month low; last at 15,320, down 545 pts or 3.4%, with a total turnover of $88.5 billion.
Pharmaceuticals were sold off. $REMEGEN(09995.HK)$ once collapsed 27.5% to $22.8; last at $24.9, down 21%.
$CLOVER BIO-B(02197.HK)$ nosedived 9.6% to $0.47, hitting record low. $VIVA BIOTECH(01873.HK)$ ...

Moomoo AI

Dec 28, 2023 10:11

Akeso's low P/S ratio indicates shareholder discomfort over its weak future revenue forecast. The market's gloomy sentiment about the company's growth prospects affects the low P/S ratio.

Little Excitement Around Akeso, Inc.'s (HKG:9926) Revenues

Moomoo AI

Nov 16, 2023 07:43

Akeso's strong net cash position and high liquidity suggest a low risk in its debt usage. The large conversion rate of EBIT to free cash flow also signals a positive financial health and potential profitability.

Is Akeso (HKG:9926) A Risky Investment?

ETFWorldSavior

Jun 8, 2023 10:42

ColumnsAnxin International - Pharmaceutical Industry Biweekly Report: The results of Chinese medicine decoction pieces combined selection landing, 2023ASCO abstract released

Key points:
1. Hang Seng Index fell 2.57% in the first two weeks (2023/05/22 to 2023/06/02), with all 12 Hang Seng industries falling. Among them, the Hang Seng healthcare sector fell 1.51%, outperforming the Hang Seng Index by 1.06 percentage points, ranking third among the 12 Hang Seng industries
2. On May 22, the results of the f...

BrandonnW

Oct 8, 2021 16:42

$AKESO(09926.HK)$ Excellent clinical data, focus on product launch and data disclosure
Phase II clinical trial of AK112 combined with paclitaxel and chemotherapy in advanced non-small cell lung cancer
Objective sustained release rate (ORR) 53.8%, disease control rate (DCR) 100%, grade 3 or above treatment
The incidence of related adverse events was 13.5%. In combination with the PARP inhibitor olaparil for ovarian cancer
Phase Ib/II clinical, ORR/DCR 40.0%/86.7%. We expect it to be around 2024 on the market.

No comment yet

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall